Biotie Therapies (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Biotie Therapies" in English language version.

refsWebsite

Global rank English rank

11web.archive.org

1^st place

1^st place

low place

low place

14^th place

14^th place

2genengnews.com

low place

6,625^th place

low place

low place

1seekingalpha.com

5,344^th place

3,420^th place

low place

low place

1michaeljfox.org

low place

low place

acorda.com

ir.acorda.com

"Acorda Discontinues Tozadenant Development Program". Investor News (Press release). Acorda. November 20, 2017. Retrieved 2019-09-24.^{[self-published source]}

archive.today

Biotie Therapies Oyj Company Description Business Week^{[dead link‍]}
[1] Stock Exchange release 23 November 2011

biotie.com

"The acquisition of Synosia Therapeutics Holding AG completed" (Press release). Biotie Therapies. February 2, 2011. Archived from the original on August 19, 2011.^{[self-published source]}
"Biotie.com, Collaborations". February 14, 2013. Archived from the original on April 27, 2012.^{[self-published source]}
"Biotie: Selincro (nalmefene) receives European marketing authorization" (Press release). Biotie Therapies. 28 February 2013. Archived from the original on June 3, 2013.^{[self-published source]}
"Stock Exchange Release 27 February 2013" (Press release). Biotie Therapies. 27 February 2013. Archived from the original on June 3, 2013.^{[self-published source]}
"Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder" (Press release). Biotie Therapies. December 27, 2012. Archived from the original on March 4, 2013.^{[self-published source]}
"Biotie.com, Pipeline". February 14, 2013. Archived from the original on 2013-02-15.
Lundbeck announces start of new phase III clinical trials with nalmefene Archived December 22, 2008, at the Wayback Machine STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m
Balanced CNS and inflammation product pipeline Archived April 25, 2010, at the Wayback Machine Company website 2008-03-15
"Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson's disease". March 26, 2012. Archived from the original on 2011-12-28.
"Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD)". March 26, 2012. Archived from the original on 2011-11-13.
"Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders". March 26, 2012. Archived from the original on 2011-11-13.

genengnews.com

"Accorda Acquires Biotie Therapies for $363 Million - GEN News Highlights - GEN". 19 January 2016.
Staff (January 19, 2016). "Acorda Acquires Biotie Therapies for $363 Million". Genetic Engineering & Biotechnology News. New Rochelle, New York: Mary Ann Liebert.

hugin.info

"Financial statements 2012" (PDF). Biotie Therapies. Retrieved 9 March 2013.^{[self-published source]}

michaeljfox.org

Dolhun, Rachel (November 15, 2017). "Parkinson's Tozadenant Trial Discontinued". New York, New York: The Michael J. Fox Foundation for Parkinson's Research. Retrieved 2019-02-14.

seekingalpha.com

House, Douglas W. (5 June 2015). "Biotie Therapies on deck for U.S. debut". Seeking Alpha.

web.archive.org

"The acquisition of Synosia Therapeutics Holding AG completed" (Press release). Biotie Therapies. February 2, 2011. Archived from the original on August 19, 2011.^{[self-published source]}
"Biotie.com, Collaborations". February 14, 2013. Archived from the original on April 27, 2012.^{[self-published source]}
"Biotie: Selincro (nalmefene) receives European marketing authorization" (Press release). Biotie Therapies. 28 February 2013. Archived from the original on June 3, 2013.^{[self-published source]}
"Stock Exchange Release 27 February 2013" (Press release). Biotie Therapies. 27 February 2013. Archived from the original on June 3, 2013.^{[self-published source]}
"Biotie reports top-line data from clinical study with nepicastat (SYN117) in post-traumatic stress disorder" (Press release). Biotie Therapies. December 27, 2012. Archived from the original on March 4, 2013.^{[self-published source]}
"Biotie.com, Pipeline". February 14, 2013. Archived from the original on 2013-02-15.
Lundbeck announces start of new phase III clinical trials with nalmefene Archived December 22, 2008, at the Wayback Machine STOCK EXCHANGE RELEASE 15 December 2008 at 9.30 a.m
Balanced CNS and inflammation product pipeline Archived April 25, 2010, at the Wayback Machine Company website 2008-03-15
"Biotie.com, SYN115 (tozadenant): A highly differentiated product for Parkinson's disease". March 26, 2012. Archived from the original on 2011-12-28.
"Biotie.com, SYN117 (nepicastat) for the treatment of cocaine dependency and post traumatic stress disorder (PTSD)". March 26, 2012. Archived from the original on 2011-11-13.
"Biotie.com, Ronomilast: PDE4 inhibitor for chronic inflammatory disorders". March 26, 2012. Archived from the original on 2011-11-13.